# A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

> **NCT03337308** · PHASE3 · COMPLETED · sponsor: **Esperion Therapeutics, Inc.** · enrollment: 382 (actual)

## Conditions studied

- Hyperlipidemias

## Interventions

- **COMBINATION_PRODUCT:** Bempedoic Acid + Ezetimibe Fixed-Dose Combination
- **DRUG:** Bempedoic Acid
- **DRUG:** Ezetimibe
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03337308
- **Lead sponsor:** Esperion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-23
- **Primary completion:** 2018-06-18
- **Final completion:** 2018-07-18
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03337308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03337308, "A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03337308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*